Dreampath Diagnostics is the Global Leader in automation of traceability of patient samples in pathology.

Dreampath has just obtained a second US patent consolidating even more their leadership in the field of sample management automation and traceability.

“This is fantastic news”, said Wilhelm, Head of R&D and Operations. “We are thrilled about being rewarded for our continuous innovations in our field. We have now a strong IP portfolio in all Continents with very important claims on our field”.

Pablo Jordan, Dreampath’s CEO said “this is yet another milestone for us. We have now a large installed base of customers that trust our quality and invest on our innovations. Automation of traceability is key for pathology labs and with this second patent we strengthen even more our position”.

Dreampath will continue investing heavily on R&D and IP in order to bring innovative solutions in pathology.

Dreampath is based in Strasbourg, France and produces all its products, including the consumables, in the Rhine Valley Region in Europe. Their products are of highest quality and comply with all international standards for quality, robustness and safety.

Dreampath’s leadership, innovation and technology lies on automation of traceability of patient’s samples in pathology laboratories.